182 related articles for article (PubMed ID: 12874017)
1. CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines.
Rieger R; Kipps TJ
Cancer Res; 2003 Jul; 63(14):4128-35. PubMed ID: 12874017
[TBL] [Abstract][Full Text] [Related]
2. In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma.
Briones J; Timmerman J; Levy R
Cancer Res; 2002 Jun; 62(11):3195-9. PubMed ID: 12036933
[TBL] [Abstract][Full Text] [Related]
3. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154.
Loskog A; Tötterman TH; Böhle A; Brandau S
Cancer Gene Ther; 2002 Oct; 9(10):846-53. PubMed ID: 12224026
[TBL] [Abstract][Full Text] [Related]
4. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
Guinn BA; DeBenedette MA; Watts TH; Berinstein NL
J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049
[TBL] [Abstract][Full Text] [Related]
5. Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma.
Meziane el K; Bhattacharyya T; Armstrong AC; Qian C; Hawkins RE; Stern PL; Dermime S
Int J Cancer; 2004 Oct; 111(6):910-20. PubMed ID: 15300803
[TBL] [Abstract][Full Text] [Related]
6. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma.
Sandler AD; Chihara H; Kobayashi G; Zhu X; Miller MA; Scott DL; Krieg AM
Cancer Res; 2003 Jan; 63(2):394-9. PubMed ID: 12543793
[TBL] [Abstract][Full Text] [Related]
7. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
[TBL] [Abstract][Full Text] [Related]
8. Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma.
Takahashi S; Yotnda P; Rousseau RF; Mei Z; Smith S; Rill D; Younes A; Brenner MK
Cancer Gene Ther; 2001 May; 8(5):378-87. PubMed ID: 11477458
[TBL] [Abstract][Full Text] [Related]
9. Dendritic and tumor cell fusions transduced with adenovirus encoding CD40L eradicate B-cell lymphoma and induce a Th17-type response.
Alvarez E; Moga E; Barquinero J; Sierra J; Briones J
Gene Ther; 2010 Apr; 17(4):469-77. PubMed ID: 20010627
[TBL] [Abstract][Full Text] [Related]
10. CpG-C ISS-ODN activation of blood-derived B cells from healthy and chronic immunodeficiency virus-infected macaques.
Teleshova N; Kenney J; Williams V; Van Nest G; Marshall J; Lifson JD; Sivin I; Dufour J; Bohm R; Gettie A; Pope M
J Leukoc Biol; 2006 Feb; 79(2):257-67. PubMed ID: 16443827
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of antigen-presenting ability of B lymphoma cells by immunostimulatory CpG-oligonucleotides and anti-CD40 antibody.
Chen W; Yu Y; Shao C; Zhang M; Wang W; Zhang L; Cao X
Immunol Lett; 2001 May; 77(1):17-23. PubMed ID: 11348665
[TBL] [Abstract][Full Text] [Related]
12. Cytidine-phosphate-guanosine oligodeoxynucleotides and interferon-alpha-expressing tumor cells effectively induce dendritic cell maturation in vitro.
Hiraide A; Hiroishi K; Ishii S; Eguchi J; Imawari M
Anticancer Res; 2006; 26(1A):211-8. PubMed ID: 16475701
[TBL] [Abstract][Full Text] [Related]
13. Poly(D,L-lactic-co-glycolic acid) microsphere delivery of adenovirus for vaccination.
Wang D; Molavi O; Lutsiak ME; Elamanchili P; Kwon GS; Samuel J
J Pharm Pharm Sci; 2007; 10(2):217-30. PubMed ID: 17706180
[TBL] [Abstract][Full Text] [Related]
14. Preventive and therapeutic antitumor effect of tumor vaccine composed of CpG ODN class C and irradiated tumor cells is triggered through the APCs and activation of CTLs.
Novaković S; Stegel V; Kopitar A; Ihan A; Novaković BJ
Vaccine; 2007 Nov; 25(49):8241-56. PubMed ID: 17980936
[TBL] [Abstract][Full Text] [Related]
15. Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction.
Hessel EM; Chu M; Lizcano JO; Chang B; Herman N; Kell SA; Wills-Karp M; Coffman RL
J Exp Med; 2005 Dec; 202(11):1563-73. PubMed ID: 16314434
[TBL] [Abstract][Full Text] [Related]
16. Long-term reversal of hypercholesterolemia in low density lipoprotein receptor (LDLR)-deficient mice by adenovirus-mediated LDLR gene transfer combined with CD154 blockade.
Stein CS; Martins I; Davidson BL
J Gene Med; 2000; 2(1):41-51. PubMed ID: 10765504
[TBL] [Abstract][Full Text] [Related]
17. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles.
Mui B; Raney SG; Semple SC; Hope MJ
J Pharmacol Exp Ther; 2001 Sep; 298(3):1185-92. PubMed ID: 11504819
[TBL] [Abstract][Full Text] [Related]
18. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
Tewary P; Sukumaran B; Saxena S; Madhubala R
Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055
[TBL] [Abstract][Full Text] [Related]
19. CpG oligodeoxynucleotide-induced immunity prevents growth of germinal center-derived B lymphoma cells.
Ponzio NM; Cutro S; Hu J; Marzouk A; Marshall JD
Int Immunopharmacol; 2006 Dec; 6(13-14):2057-68. PubMed ID: 17161362
[TBL] [Abstract][Full Text] [Related]
20. Gene transfer of noncleavable cell surface mutants of human CD154 induces the immune response and diminishes systemic inflammatory reactions.
Masuta Y; Kato K; Tomihara K; Nakamura K; Sasaki K; Takahashi S; Hamada H
J Immunother; 2007 Oct; 30(7):694-704. PubMed ID: 17893562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
